UNSPSC 51285505: Oxibetaine

This classification denotes an anti-lipidemic agent with the molecular formula C6H13NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y0WVV18VUI, chemically known as n-(2-hydroxyethyl) n,n-dimethylammonioacetat but generally known as oxibetaine, which bears US NIH Compound Identifier 168886. European Medicines Agency schedules Oxibetaine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09522MIG. The term OXIBETAINE is an International Non-Proprietary Name.

UNSPSC 51285505 Oxibetaine, a Commodity code, nominally covers a specific pharmaceutical ingredient, but state and local procurement activity under this code does not reflect purchasing of oxibetaine itself. Instead, the recent opportunities tagged to this code show state and local health, safety, and pharmacy benefit administrators buying naloxone (a life-saving opioid antagonist), medical and first aid supplies for emergency response, and generic pharmaceuticals through cooperative purchasing vehicles. The issuing bodies include county health departments, municipal fire services, state health and human services agencies, and multi-state cooperative purchasing alliances. The scope of work spans acute pharmaceutical procurement (naloxone and drug deactivation systems), inventory-intensive medical supply chains serving emergency responders (endotracheal tubes, cardiac monitoring equipment, respiratory devices), and large-scale generic and OTC pharmaceutical distribution through authorized wholesaler networks with compliance to Good Manufacturing Practices and Drug Supply Chain Security Act requirements.

Geographic activity concentrates in Florida (Seminole County), Texas (Texas Health and Human Services Commission), Minnesota (MMCAP covering Minnesota and Oregon), and the broader multi-state cooperative purchasing footprint. Representative recent opportunities include Seminole County's IFB60459723LAS for 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries (due July 26, 2023); the City of Tampa's IFB 26P00145 for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division with an estimated contract amount of $700,000.00 and a March 13, 2026 deadline, restricted to certified Small Local Business Enterprises with a 5 percent bid discount; and MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products requiring proposals by March 26, 2026. The Texas HHS Commission's RFI HHS0017013 (April 3, 2026 response deadline) signals forward intent to establish direct-to-manufacturer prescription programs, though this RFI remains exploratory rather than a formal award vehicle. The mismatch between the code's nominal substance (oxibetaine) and actual purchasing activity suggests the code is being applied inconsistently by state and local procurement offices posting these health-sector opportunities.